Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anticholinergic drugs in overactive bladder].

J Muhlstein1, B Deval

  • 1Maternité régionale A. Pinard, 10, rue du Docteur Heydenreich, CS 74213, 54042 Nancy cedex, France.

Gynecologie, Obstetrique & Fertilite
|January 8, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on non-invasive treatment for female overactive bladder.

Journal of gynecology obstetrics and human reproduction·2020
Same author

[How i do… Laparoscopic ventral rectopexy using a synthetic mesh].

Gynecologie, obstetrique, fertilite & senologie·2019
Same author

[Application of laser in uro-gynecology: Warning!]

Gynecologie, obstetrique, fertilite & senologie·2019
Same author

Add-ons in IVF programme - Hype or Hope?

Facts, views & vision in ObGyn·2016
Same author

[X-ray pelvimetry practice survey in Northeast French maternities].

Journal de gynecologie, obstetrique et biologie de la reproduction·2014
Same author

[Post-rape pregnancy].

Gynecologie, obstetrique & fertilite·2013
Same journal

[How I do… to see the sliding sign by transvaginal ultrasonography?]

Gynecologie, obstetrique & fertilite·2016
Same journal

[Cell-free fetal DNA screening tests for trisomy 21].

Gynecologie, obstetrique & fertilite·2016
Same journal

[Lucy's cancer(s): A prehistorical origin?]

Gynecologie, obstetrique & fertilite·2016
Same journal

[Male age in assisted reproductive technologies: Is there a limit?]

Gynecologie, obstetrique & fertilite·2016
Same journal

[Iodinated contrast in pregnant women and neonatal thyroid function].

Gynecologie, obstetrique & fertilite·2016
Same journal

[Breast cancer and diabetes mellitus: Complex interactions].

Gynecologie, obstetrique & fertilite·2016
See all related articles

Overactive bladder syndrome (OAB) affects millions, causing urgency and frequent urination. Research is expanding OAB treatments to improve quality of life and reduce side effects.

Area of Science:

  • Urology
  • Geriatrics
  • Pharmacology

Context:

  • Overactive bladder syndrome (OAB) affects 16-45% of the general population, with an estimated 34 million people in the USA.
  • Symptoms include urinary urgency, frequency, and nocturia, often impacting quality of life.
  • OAB prevalence increases with age and affects both men and women.

Purpose:

  • To review the current understanding and treatment landscape of overactive bladder syndrome.
  • To highlight the impact of OAB on patients' daily lives and mental well-being.
  • To discuss advancements in OAB therapeutic options.

Summary:

  • OAB is characterized by abrupt, uncontrollable urges to urinate, leading to high urinary frequency.
  • Existing treatments include medications like oxybutynin, tolterodine, solifenacin, darifenacin, and trospium chloride.

Related Experiment Videos

  • Emerging therapies involve new formulations, administration routes (intravesical, transdermal, vaginal, rectal), and novel active ingredients (botulinum toxin, capsaicin, resiniferatoxin).

    • Impact:

    • OAB significantly diminishes quality of life, potentially causing depression, sleep disturbances, and sexual dysfunction.
    • New therapeutic strategies aim to maximize symptom reduction while minimizing adverse effects.
    • Ongoing research seeks to provide more effective and tolerable treatments for OAB patients.